



**Kevin Bacon**

State Senator

3<sup>rd</sup> District

**Ohio Senate**

Senate Building  
1 Capitol Square  
Columbus, Ohio 43215  
(614) 466-8064

**Committees:**

Civil Justice- Chair

Insurance - Vice Chair

Criminal Justice

Finance – Higher Ed Subcommittee

Financial Institutions

Criminal Justice

Public Utilities

Transportation, Commerce, and Labor

**Review Testimony  
Cystic Fibrosis Legislative Task Force**

**May 3<sup>rd</sup>, 2016**

**Senator Kevin Bacon  
Sunset Review Committee**

Good afternoon, Chairman Jordan and members of the Sunset Review Committee. Thank you for the opportunity to testify on behalf of the Cystic Fibrosis Legislative Task Force.

The Cystic Fibrosis Legislative Task Force was created in Senate Bill 171 of the 129<sup>th</sup> General Assembly to “study and make recommendations on issues pertaining to the care and treatment of individuals with cystic fibrosis” (ORC 101.38). Specifically, the task force was assigned the responsibility of examining and making recommendations on the use of prescription drug and innovative therapies for medically handicapped children—and the program for adults with cystic fibrosis administered by the Department of Health. The task force also has discretion to examine other issues that relate to cystic fibrosis as it deems appropriate. The task force members receive no compensation except to the extent that serving as a member is part of the individual’s regular duties of employment.

The task force consists of:

1. Three members of the Senate, two appointed by the Senate President and one appointed by the Senate Minority Leader;
2. Three members of the Ohio House of Representatives, two appointed by the Speaker, and one appointed by the House Minority Leader;
3. Three members, at least two of whom have been diagnosed with cystic fibrosis or are relatives of individuals who have been diagnosed with cystic fibrosis, appointed by the Senate President;
4. Three members, at least two of whom have been diagnosed with cystic fibrosis or are relatives of individuals who have been diagnosed with cystic fibrosis, appointed by the Speaker of the House.

Since 2005, the Cystic Fibrosis Legislative Task Force has been involved in reviewing the treatment and care of individuals with cystic fibrosis. As one of six legislators currently appointed to this task force, I am grateful for the opportunity to testify and would be happy to answer any questions from the committee at this time.